Cystic fibrosis drug set for rejection
A €220,000 `wonder drug' to treat cystic fibrosis is set to be rejected for use in the Irish health service.
A €220,000 "wonder drug" to treat cystic fibrosis (CF) is set to be rejected for use in the Irish health service after the manufacturer was told there were serious obstacles to the Irish taxpayer covering the cost.
Kalydeco, which is manufactured by Vertex Pharmaceuticals, is the first and only drug that treats the underlying cause of CF rather than the symptoms of the condition.
It is too early to say whether Kalydeco will be a...
Subscribe from just €1 for the first month!
With any subscription you will have access to
Unlimited multi-device access to our iPad, iPhone and Android Apps
Unlimited access to our eReader library
Exclusive daily insight and opinion seven days a week
Create alerts to never miss a subject that matters to you
Get access to exclusive offers for subscribers on gifts and experiences
Get content from Business Post, Business Post Magazines, Connected, Tatler and Food & Wine